Purification of the human fibroblast growth factor 2 using novel animal-component free materials.
Animal-component free
Heparin affinity chromatography
Human fibroblast growth factor 2 (hFGF-2)
Mixed-mode chromatography
Pseudo-affinity chromatography
Journal
Journal of chromatography. A
ISSN: 1873-3778
Titre abrégé: J Chromatogr A
Pays: Netherlands
ID NLM: 9318488
Informations de publication
Date de publication:
30 Aug 2020
30 Aug 2020
Historique:
received:
05
03
2020
revised:
11
06
2020
accepted:
22
06
2020
entrez:
17
8
2020
pubmed:
17
8
2020
medline:
22
9
2020
Statut:
ppublish
Résumé
This paper analyzes the use of animal-component free chromatographic materials for the efficient purification of the human fibroblast growth factor 2 (hFGF-2). hFGF-2 is produced in Escherichia coli and purified via three different chromatography steps, which include a strong cation exchange chromatography as a capture step, followed by heparin affinity chromatography and an anion exchange chromatography as a polishing step. The affinity chromatography step is based on the animal-derived material heparin. Chemically produced ligands provide a viable alternative to animal-derived components in production processes, since they are characterized by a defined structure which leads to reproducible results and a broad range of applications. The alternative ligands can be assigned to adsorber of the mixed-mode chromatography (MMC) and pseudo-affinity chromatography. Eight different animal-component free materials used as adsorbers in MMC or pseudo-affinity chromatography were tested as a substitute for heparin. The MMCs were cation exchangers characterized with further functional residues. The ligands of the pseudo-affinity chromatography were heparin-like ligands which are based on heparin's molecular structure. The alternative methods were tested as a capture step and in combination with another chromatographic step in the purification procedure of hFGF-2. In each downstream step purity, recovery and yield were analysed and compared to the conventional downstream process. Two types of MMC - the column Foresight
Identifiants
pubmed: 32797846
pii: S0021-9673(20)30644-0
doi: 10.1016/j.chroma.2020.461367
pii:
doi:
Substances chimiques
Ligands
0
Fibroblast Growth Factor 2
103107-01-3
Heparin
9005-49-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
461367Informations de copyright
Copyright © 2020. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.